Not saying Diane Simeone's talk will necessarily have an immediate impact on the CRIS pps, however...
1. She has her own prime time one-hour slot.
2. Likely she will focus on one or more indications beyond bcc.
3. One of her doctoral candidates recently published "A detailed understanding of the cross-talk between tumor and stromal cells may hold clues to affectively targeting pancreatic tumors in new ways. We have identified that Hedgehog (Hh) signaling is one of the important feedback mechanisms between pancreatic tumor cells and the infiltrating stroma. Targeting paracrine Hh signaling in the tumor stroma can have significant effects on tumor biology, including reduction in metastatic spread, changes in tumor cell differentiation, decreases in tumor desmoplasia, and disruption of the cancer stem cell population. Future studies will be aimed at understanding how paracrine Hh signaling and downstream Hh- target genes affect the biological function of the tumor mesenchyme and of the tumor cells themselves and how this may translate to more effective therapies for pancreatic cancer."
4. IMO, it is the ultimate approval of a second indication for GDC-0449 that opens the floodgates. See point #2 above.
Assuming FDA approves the first indication for GDC-0449 re BCC on or before March 8th, what would be the earliest there would be "ultimate" approval for a second indication, presumably one targeting pancreatic cancer? 2 years, three years? Again assuming approval for BCC, that process has taken six years. So I doubt the price of this stock exceeds $6 over the next two years even if all goes well by March 8th. BCC application too limited and I do not see approval of drug for operable BCC down the road.